Literature DB >> 17426932

[Pathobiology of acute myeloid leukemia].

Oliver Christ1, Michaela Feuring-Buske, Wolfgang Hiddemann, Christian Buske.   

Abstract

Acute myeloid leukemia (AML) arises from the clonal expansion of primitive myeloid precursor cells. A series of genetic alterations leads to a perturbation of normal developmental programs affecting growth, maturation and differentiation of hematopoietic cells. As a consequence, immature leukemic cells that have the ability to divide and proliferate, but lack normal differentiation mechanisms, accumulate in the bone marrow. This, in turn, leads to a severe impairment of normal hematopoiesis. Over the last several years, a number of clinical and basic research studies have elucidated important pathogenetic mechanisms leading to the initiation of AML. The identification of numerous chromosomal aberrations and mutations specific for AML has deepened our insights into the biology of AML and has allowed to improve our diagnostic tools, the definition of prognostic subgroups and therapeutic concepts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17426932     DOI: 10.1007/s00063-007-1035-2

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  3 in total

1.  Expression of Eph A4, Eph B2 and Eph B4 receptors in AML.

Authors:  Tomasz Wrobel; Joanna Pogrzeba; Ewa Stefanko; Marcin Wojtowicz; Bozena Jazwiec; Justyna Dzietczenia; Grzegorz Mazur; Kazimierz Kuliczkowski
Journal:  Pathol Oncol Res       Date:  2014-04-25       Impact factor: 3.201

2.  Significance of OCT1 Expression in Acute Myeloid Leukemia.

Authors:  Ewa Stefanko; Justyna Rybka; Bożena Jaźwiec; Olga Haus; Sylwia Stąpor; Kazimierz Kuliczkowski; Tomasz Wróbel
Journal:  Pathol Oncol Res       Date:  2016-12-26       Impact factor: 3.201

3.  Daemonorops draco Blume Induces Apoptosis Against Acute Myeloid Leukemia Cells via Regulation of the miR-216b/c-Jun.

Authors:  Moon Nyeo Park; Hee Won Jeon; Md Ataur Rahman; Se Sun Park; Se Yun Jeong; Ki Hyun Kim; Sung-Hoon Kim; Woojin Kim; Bonglee Kim
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.